Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy
Season 3, Episode 31, Aug 20, 2020, 07:22 PM
Share
Subscribe
In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.